MIM
PRVB

MetLife Investment Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

MetLife Investment Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-33,150
Closed -$799K – 3031
2023
Q1 		$799K Buy
33,150
+2,366
+8% +$29.7K 0.01% 1352
2022
Q4 		$325K Hold
30,784
– – ﹤0.01% 1916
2022
Q3 		$139K Buy
30,784
+21,876
+246% +$99.7K ﹤0.01% 2507
2022
Q2 		$35.6K Sell
8,908
-23,508
-73% -$111K ﹤0.01% 2823
2022
Q1 		$237K Buy
32,416
+25,003
+337% +$150K ﹤0.01% 2253
2021
Q4 		$41.7K Sell
7,413
-13,272
-64% -$84.3K ﹤0.01% 2469
2021
Q3 		$132K Buy
20,685
+12,586
+155% +$80.9K ﹤0.01% 2312
2021
Q2 		$68.3K Sell
8,099
-13,497
-62% -$109K ﹤0.01% 2417
2021
Q1 		$227K Buy
21,596
+1,969
+10% +$27.7K ﹤0.01% 1988
2020
Q4 		$332K Hold
19,627
– – ﹤0.01% 1701
2020
Q3 		$252K Hold
19,627
– – ﹤0.01% 1720
2020
Q2 		$277K Buy
+19,627
New +$248K ﹤0.01% 1706

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

MetLife Investment Management's PRVB Position: Q2 2023 in Review

MetLife Investment Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 33,150 shares — an estimated $799K sold.

MetLife Investment Management first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $799K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • MetLife Investment Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • MetLife Investment Management sold 33,150 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $799K.
  • MetLife Investment Management first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • MetLife Investment Management's Provention Bio, Inc. Common Stock position peaked at $799K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on MetLife Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.